Format

Send to

Choose Destination
See comment in PubMed Commons below
Rev Bras Hematol Hemoter. 2012;34(2):150-5. doi: 10.5581/1516-8484.20120035.

Molecular biology of Philadelphia-negative myeloproliferative neoplasms.

Author information

  • 1Hematology Department, Hospital Israelita Albert Einstein - HIAE, São Paulo, SP, Brazil.

Abstract

Myeloproliferative neoplasms are clonal diseases of hematopoietic stem cells characterized by myeloid hyperplasia and increased risk of developing acute myeloid leukemia. Myeloproliferative neoplasms are caused, as any other malignancy, by genetic defects that culminate in the neoplastic phenotype. In the past six years, since the identification of JAK2V617F, we have experienced a substantial increase in our knowledge about the genetic mechanisms involved in the genesis of myeloproliferative neoplasms. Mutations described in several genes have revealed a considerable degree of molecular homogeneity between different subtypes of myeloproliferative neoplasms. At the same time, the molecular differences between each subtype have become clearer. While mutations in several genes, such as JAK2, myeloproliferative leukemia (MPL) and LNK have been validated in functional assays or animal models as causative mutations, the roles of other recurring mutations in the development of disease, such as TET2 and ASXL1 remain to be elucidated. In this review we will examine the most prevalent recurring gene mutations found in myeloproliferative neoplasms and their molecular consequences.

KEYWORDS:

Janus kinase 2; Leukemia, myeloid, acute; Myeloproliferative disorders; Polycythemia vera; Primary myelofibrosis; Thrombocythemia, essential

PMID:
23049405
PMCID:
PMC3459398
DOI:
10.5581/1516-8484.20120035
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Support Center